Shanghai RAAS shareholder to increase stake amid buyback silence

Shanghai RAAS Blood Products (SZSE:002252) announced its controlling shareholder, Haikang (Qingdao) Medical Technology, intends to increase its stake in the company. Haikang plans to invest between RMB 250 million and RMB 500 million over the next six months, excluding periods when trading is restricted. This move aims to bolster investor confidence in Shanghai RAAS's prospects. Haikang currently holds 21.11% of Shanghai RAAS's shares and controls 27.70% through a voting rights agreement with Grifols, S.A.